Table 2.
Multivariate Cox regression analyses for cancer-specific mortality and overall mortality in the total cohort and matched population
| Outcome | Treatment | Nonadjusted model, HR (95% CI) | Adjusted model, HR (95% CI) | PSM model, HR (95% CI) |
|---|---|---|---|---|
| CSM | AS/WW | Reference | Reference | Reference |
| Focal therapy | 1.19 (0.29–4.89) | 0.98 (0.23–4.11) | 1.26 (0.24–6.51) | |
| P | 0.810 | 0.977 | 0.782 | |
| OM | AS/WW | Reference | Reference | Reference |
| Focal therapy | 1.76 (1.33–2.33) | 1.35 (1.02–1.79) | 1.26 (0.92–1.74) | |
| P | <0.001 | 0.037 | 0.149 |
Adjusted model: adjusted for age, PSA level, race, T stage, and total Gleason score. PSM model: matched according to age, PSA level and T stage. CSM: cancer-specific mortality; OM: overall mortality; AS: active surveillance; WW: watchful waiting; PSM: propensity score matching; PSA: prostate-specific antigen; HR: hazard ratio; CI: confidence interval